New Epidemiologic Aspects in Head and Neck Cancers
Fig. 2.1 Europe, 2012, head and neck cancers incidence. H&N = lip, tongue, oral cavity, pharynx, larynx, salivary glands, nasopharynx and nasal cavities (GLOBOCAN 2012 (IARC) – 2.11.2015) Fig. 2.2…
The “Make Sense Campaign”: An Initiative of the European Head and Neck Society
Fig. 1.1 ‘About Face I’ survey responses to question, “Are you familiar with the term head and neck cancer?” Although the majority of respondents recognised that HNC affects the pharynx…
Comprehensive Overview: Definitive Radiotherapy and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer
Study/author/year No. patients Sites/no. pts. OP/OC/HP/L Stage (UICC) Fractionation schedule OTT (weeks) Total dose in tt.-arms LC/LRC (%) PFS (%) OS (%) Acute toxicities Late morbidities Pinto et al. (1991)…
Pros and Cons of Endoscopic Surgery
Fig. 7.1 (a) Endoscopic view of a squamous cell carcinoma (SCC) of the left vocal fold. (b) Preoperative CT scan of the same lesion showing the invasion of the left…
Oncologic Dentistry and Implants
Figs. 8.1 and 8.2 A superior aesthetic result from an implant-supported prosthesis rivalling any potential result achievable with autogenous tissue transfer Head and neck patients offer a unique set of…
The Biology of Head and Neck Cancer
Fig. 3.1 Growth factor independence leads to sustained signalling in pathways that control essential biological functions. Binding of ligand to the extracellular ligand-binding domain leads to receptor dimerisation and activation…
Palliative Care in Patients with Head and Neck Cancer
Author No. of Pts Treatment Response rate (%) Median survival (months) First–line treatment chemotherapeutic agents Jacobs 245 PF P F 32a 17 13 5.5 5.0 6.1 Forastiere 277 PF CF…
Systemic Treatments: Chemotherapy and Targeted Therapies
Regimens N ORR (%) Median survival (months) Reference Cisplatin/5-FU 249 32 % 5.5 months [26] vs. Cisplatin 17 % 5 months vs. 5-FU 13 % 6.1 months Cisplatin/methotrexate/bleomycin/vincristine…
Molecular Imaging in Head and Neck Squamous Cell Carcinoma Patients
Tracer First author, year Type Target/process 18F-FMISO Rajendran, 2006 [14] Nitroimidazole Hypoxia 18F-FAZA Mortensen, 2012 [15] Nitroimidazole Hypoxia 18F-HX4 Zegers, 2015 [16] Nitroimidazole Hypoxia 18F-EF5 Komar, 2014 [17] Nitroimidazole Hypoxia…
Issues at End of Life
The broken line or box is meant to signify the existential element to health and illness. One should consider the total needs of the patient and not just their pain…
